1. Home
  2. AFMD vs LICY Comparison

AFMD vs LICY Comparison

Compare AFMD & LICY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AFMD
  • LICY
  • Stock Information
  • Founded
  • AFMD 2000
  • LICY 2016
  • Country
  • AFMD Germany
  • LICY Canada
  • Employees
  • AFMD N/A
  • LICY N/A
  • Industry
  • AFMD Biotechnology: Pharmaceutical Preparations
  • LICY Environmental Services
  • Sector
  • AFMD Health Care
  • LICY Industrials
  • Exchange
  • AFMD Nasdaq
  • LICY Nasdaq
  • Market Cap
  • AFMD 45.6M
  • LICY 39.7M
  • IPO Year
  • AFMD 2014
  • LICY N/A
  • Fundamental
  • Price
  • AFMD $1.27
  • LICY $1.50
  • Analyst Decision
  • AFMD Strong Buy
  • LICY Hold
  • Analyst Count
  • AFMD 5
  • LICY 2
  • Target Price
  • AFMD $13.50
  • LICY $4.13
  • AVG Volume (30 Days)
  • AFMD 498.2K
  • LICY 1.0M
  • Earning Date
  • AFMD 11-14-2024
  • LICY 11-07-2024
  • Dividend Yield
  • AFMD N/A
  • LICY N/A
  • EPS Growth
  • AFMD N/A
  • LICY N/A
  • EPS
  • AFMD N/A
  • LICY N/A
  • Revenue
  • AFMD $6,287,085.00
  • LICY $27,400,000.00
  • Revenue This Year
  • AFMD N/A
  • LICY $55.96
  • Revenue Next Year
  • AFMD $28.44
  • LICY $14.13
  • P/E Ratio
  • AFMD N/A
  • LICY N/A
  • Revenue Growth
  • AFMD N/A
  • LICY N/A
  • 52 Week Low
  • AFMD $1.40
  • LICY $1.22
  • 52 Week High
  • AFMD $8.95
  • LICY $15.36
  • Technical
  • Relative Strength Index (RSI)
  • AFMD 16.00
  • LICY 34.74
  • Support Level
  • AFMD $1.40
  • LICY $1.42
  • Resistance Level
  • AFMD $2.21
  • LICY $2.02
  • Average True Range (ATR)
  • AFMD 0.24
  • LICY 0.15
  • MACD
  • AFMD -0.08
  • LICY -0.03
  • Stochastic Oscillator
  • AFMD 3.33
  • LICY 8.05

About AFMD Affimed N.V.

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

About LICY Li-Cycle Holdings Corp.

Li-Cycle Holdings Corp is a lithium-ion battery resource recovery and lithium-ion battery recycler. The company's proprietary process Spoke and Hub recycling process is designed at its Spokes, to process battery manufacturing scrap and end-of-life batteries to produce black mass and other intermediate products, and at its Hubs, to process black mass to recover raw materials, including but not limited to lithium carbonate, cobalt sulphate, and nickel sulphate.

Share on Social Networks: